Johnson & Johnson 8-K filings

Johnson & Johnson announced the retirement of Executive Vice President Jennifer Taubert, with Tom Cavanaugh appointed to succeed her, effective September 1, 2026.

Johnson & Johnson completes acquisition of Firefly Bio for $1 billion and enters strategic collaboration with Sail Biomedicines, impacting 2026 and 2027 EPS guidance.

Johnson & Johnson announced robust second-quarter 2026 results, with sales reaching $25.3 billion and earnings per share at $2.27, leading the company to increase its full-year financial guidance.

Johnson & Johnson announced strong first-quarter 2026 results, with sales up 9.9% and earnings per share of $2.14, leading the company to raise its full-year 2026 guidance.

Johnson & Johnson announced robust fourth-quarter and full-year 2025 financial results, driven by strong operational growth and significant innovation across its Innovative Medicine and MedTech segments.

Johnson & Johnson reported strong third-quarter 2025 results, raising its full-year sales outlook, and announced its intent to separate its Orthopaedics business, DePuy Synthes.

Johnson & Johnson announced the election of John Morikis, former Chairman, President and CEO of The Sherwin-Williams Company, to its Board of Directors.

Johnson & Johnson announced robust second-quarter 2025 financial results, with reported sales up 5.8% to $23.7 billion and adjusted EPS of $2.77, leading to an increased full-year guidance.

Johnson & Johnson announced the election of Daniel Pinto, President of JPMorganChase, to its Board of Directors, effective July 1, 2025.

Johnson & Johnson reports the retirement of a board member, the election of directors, and the results of votes on executive compensation and shareholder proposals at its 2025 Annual Meeting.

Johnson & Johnson announces a 2.4% increase in first-quarter sales to $21.9 billion and a 4.8% increase in the quarterly dividend, marking the 63rd consecutive year of dividend growth.

Johnson & Johnson will reverse approximately $7 billion in reserves after the U.S. Bankruptcy Court denied its subsidiary's request to confirm its proposed prepackaged bankruptcy plan related to talc claims.

Johnson & Johnson successfully completed a public offering of \$4 billion in notes with maturities ranging from 2029 to 2055.

Johnson & Johnson completed a public offering of $5 billion in notes to fund its acquisition of Intra-Cellular Therapies, Inc.

Johnson & Johnson announced a 5.3% increase in Q4 reported sales and issued a strong 2025 guidance, highlighting a transformative year marked by growth and innovation.

Johnson & Johnson announced a 5.3% increase in fourth-quarter sales and a 4.3% increase in full-year sales for 2024, alongside positive guidance for 2025.

Johnson & Johnson announced a 5.2% increase in reported sales for Q3 2024, alongside a decrease in earnings per share due to a one-time charge and acquired IPR&D.

Johnson & Johnson's subsidiary, Red River Talc LLC, has filed for Chapter 11 bankruptcy to resolve all current and future ovarian cancer claims related to talc litigation, increasing its settlement commitment to approximately $8 billion.

Johnson & Johnson reports the retirement of Director D.S. Davis and the successful transition of Audit Committee Chair responsibilities to D. Adamczyk.

Johnson & Johnson's Chief Human Resources Officer, Peter Fasolo, will retire at the end of the year, with Kristen Mulholland appointed as his successor, effective October 1, 2024.

Johnson & Johnson announced a 4.3% increase in reported sales to $22.4 billion for the second quarter of 2024, driven by operational growth and new product pipeline advancements.

Johnson & Johnson successfully closed a $5.7 billion debt offering, split between U.S. dollar and euro-denominated notes, to finance its acquisition of Shockwave Medical.

Johnson & Johnson finalized a debt-for-equity exchange, eliminating its remaining stake in Kenvue and satisfying $3.6 billion in commercial paper.

Johnson & Johnson announced a proposed reorganization plan to resolve the majority of ovarian cancer talc claims for a present value of approximately $6.475 billion.

Johnson & Johnson's Board of Directors approved amended and restated bylaws and held its 2024 annual shareholder meeting on April 25, 2024.

Johnson & Johnson announced a 2.3% increase in first-quarter reported sales to $21.4 billion, alongside an increase to the midpoint of their full-year operational sales guidance.

Johnson & Johnson announced a 2.3% increase in first-quarter sales, a 12.4% increase in adjusted EPS, and a 4.2% increase in the quarterly dividend.

Johnson & Johnson announced a 7.3% increase in fourth-quarter sales and a 6.5% increase in full-year sales for 2023, driven by strong performance in both Innovative Medicine and MedTech segments.